Friday, November 20, 2026
Breaking
Africa

Guinea-Bissau suspends controversial US-funded Hepatitis B vaccine on newborns after backlash 

Advertisement

Guinea-Bissau has halted a controversial United States-backed study that planned to investigate the effects of administering the hepatitis B vaccine to newborns, following criticism from vaccine experts over its scientific basis and ethical implications.

The lead researcher, Danish scientist Frederik Schaltz-Buchholzer, confirmed on Wednesday that the project would not proceed in the West African country because the required government approval had not been granted.

According to The Guardian, thue proposed study was expected to receive $1.6m from the United States Centres for Disease Control and Prevention (CDC), alongside another $1.6m from private donors, including the Pershing Square Foundation and the Bluebell Foundation.

In a LinkedIn post, Schaltz-Buchholzer said it was “now clear” that the study “will not move forward in Guinea-Bissau”.

The country’s Health Minister, Quinhin Nantote, had earlier denied that the trial would proceed, telling The Guardian in Portuguese that the claim was “not even remotely true”.

The proposed trial was designed by Danish researchers, including Schaltz-Buchholzer, Christine Stabell Benn and Peter Aaby.

The researchers intended to investigate whether administering the hepatitis B vaccine alongside the Bacillus Calmette-Guérin vaccine, commonly known as BCG, could influence childhood mortality beyond the vaccines’ protection against their target diseases.

Their hypothesis was that live vaccines such as BCG might provide additional health benefits, and that administering the hepatitis B vaccine alongside them could potentially affect those benefits.

However, the proposal attracted criticism from vaccine experts who questioned the scientific justification for the study and raised concerns about the ethics of withholding an established vaccine from some newborns.

Paul Offit, a vaccine expert at the Children’s Hospital of Philadelphia, described the hypothesis as “fanciful” and argued that the funding should instead be used to protect children against hepatitis B.

“The solution is clear here: take the money and vaccinate as many kids as you can,” Offit said.

He also questioned the scientific basis of the proposal, saying there was no evidence supporting the hypothesis and that it did not make biological sense.

The proposed study also raised concerns about whether parents could make a genuinely voluntary decision about their children’s participation.

Advertisement

Critics argued that parents might feel pressured to enrol their newborns because participation could give their children a chance of receiving the hepatitis B vaccine, while those who declined would not receive it through the study.

Danish researcher Henrik Støvring, who has co-published research questioning previous work from the Bandim Health Project, challenged the proposed consent arrangement.

“If they decide to participate in the trial, they have a 50% chance of getting the vaccine for their children. But if they stay out, they have a 0% chance of getting the vaccine. So how can you say that’s a non-coercive informed consent?” he asked.

The controversy also fuelled public distrust in Guinea-Bissau, where some residents questioned why the effects of a long-established vaccine were being investigated through a study involving African newborns.

According to The Guardian, the Guinea-Bissau government took control of the researchers’ vaccines after officials searched the offices of the Bandim Health Project on Monday.

The proposed study had drawn attention because it involved newborns and the withholding of a vaccine that international health authorities recommend administering shortly after birth.

The World Health Organisation recommends that all infants receive their first dose of the hepatitis B vaccine as soon as possible after birth, preferably within 24 hours, followed by at least two additional doses.

WHO spokesperson Tarik Jašarević said the organisation remained committed to working with governments, researchers and partners to ensure newborns received timely protection against the disease.

Offit also stressed the importance of vaccination, noting that Guinea-Bissau needed to expand access to hepatitis B immunisation because of the country’s high burden of chronic infection.

Guinea-Bissau Plans Universal Birth-Dose Vaccination

Despite the controversy surrounding the proposed trial, Guinea-Bissau plans to introduce universal hepatitis B vaccination at birth in 2028, according to The Guardian.

The United States CDC had not responded to the newspaper’s questions about whether the funding originally earmarked for the study would instead be redirected towards the vaccine rollout.

The suspension leaves the proposed research unable to proceed in Guinea-Bissau without the necessary government approval, while questions remain over the future use of the funding.

Advertisement
Got News? Report it to DDM. Send a tip